Market: NMS |
Currency:
Address:
📈 PELI Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
-
-
Net Income Growth Range (1Y):
-
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for PELI
No earnings history available for this symbol.
📰 Related News & Research
-
Sichuan Biokin Pharmaceutical Hong Kong IPO: Innovative Oncology Pipeline, Growth Strategies & Global Expansion (2025 Prospectus Highlights)
January 17, 2026
Baili Pharmaceutical: Hong Kong IPO Analysis, Offer Details, Financials & Outlook Baili Pharmaceutical Co., Ltd. Date of Prospectus: November 7, 2025 Baili Pharmaceutical’s Hong Kong…
-
Soilbuild Construction Group Targets S$1bn Order Book by End-2026 With Strong Pipeline and Higher Dividend Potential 1
January 16, 2026
Broker: CGS InternationalDate of Report: January 15, 2026 Excerpt from CGS International report. Report Summary Soilbuild Construction Group (SBCG) maintains a strong S\$1bn tender book…
-
Suzhou Ribo Life Science IPO: Leading the Future of siRNA Oligonucleotide Therapeutics – Company Overview, Pipeline, and Competitive Edge 1116272278
January 4, 2026
Suzhou Ribo Life Science Co., Ltd. IPO: Investor Analysis & Outlook Suzhou Ribo Life Science Co., Ltd. Date of prospectus: December 31, 2025 Suzhou Ribo…
-
Hanx Biotech IPO Prospectus 2025: Innovative Cancer & Autoimmune Drug Pipeline, Key Products HX009, HX301, HX044, Investment Highlights & Market Opportunities
December 20, 2025
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. IPO Analysis – December 15, 2025 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Date of prospectus: December 15, 2025 Hanx Biopharmaceuticals Pre-Revenue…
-
Innovative PDGF Drug Developer Huarenshengwu: Pipeline, Market Strategy, and IPO Prospectus Overview
December 20, 2025
B&K Corporation Limited IPO: In-Depth Analysis for Investors B&K Corporation Limited Date of Prospectus: December 12, 2025 B&K Corporation Limited’s Landmark Hong Kong IPO: Deep…
-
Shanghai Bao Pharmaceuticals IPO: Innovative Biologics, Pipeline, and Commercial Strategy Explained
December 6, 2025
Bao Pharmaceuticals Co., Ltd. IPO Analysis – Offer Structure, Financial Performance, Growth Strategy & Listing Outlook Company Name: Bao Pharmaceuticals Co., Ltd. Date of Prospectus:…
-
Innovative Biopharmaceutical Company Launches First Long-Acting Recombinant FSH-CTP (SJ02) in China, Advances Synthetic Biology Drug Pipeline and Global Expansion 10344351375
December 6, 2025
Shanghai Bao Pharmaceuticals Co., Ltd. – 2025 Hong Kong IPO Analysis, Growth Prospects, and Investor Outlook Shanghai Bao Pharmaceuticals Co., Ltd. Date of Prospectus: December…
-
Xuanzhu Biopharma IPO: Innovative Drug Pipeline, Commercialization Strategy, and Competitive Advantages in China’s Pharmaceutical Market
October 11, 2025
Xuanzhu Biopharma IPO Analysis: Offer Details, Financials, Risks, and Outlook (October 2025) Xuanzhu Biopharma Date of Prospectus: October 6, 2025 Xuanzhu Biopharma Launches Hong Kong…
-
Fujian Haixi Pharmaceuticals IPO: Innovative Drug Pipeline, Market Position & Growth Strategies Explained
October 11, 2025
HX Pharma IPO: Comprehensive Investor Analysis – October 2025 HX Pharma Date of Prospectus: October 9, 2025 Bold Bet on Future Growth: HX Pharma’s Landmark…
-
Digital Core REIT Investor Presentation September 2025: Pure-Play Data Centre S-REIT, Global Growth Pipeline, and Sustainable Expansion Strategies 363839
September 9, 2025
“Digital Core REIT’s \$15 Billion Growth Ambition: AI Wave, Sponsor Backing, and High-Quality Assets Power Up Shareholder Value” Digital Core REIT Sets Stage for Explosive…
🔍 View more Reports